Research LettersSerial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease
References (5)
- et al.
Visualisation and quantification of rates of atrophy in Alzheimer's disease
Lancet
(1996) - et al.
Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease
Neurology
(1997)
Cited by (148)
Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age
2021, Neurobiology of AgingCitation Excerpt :In terms of the specific brain regions impacted early during the course of AD, previous cross-sectional and longitudinal structural MRI studies indicate that individuals in the preclinical phase possess greater atrophy in a number of regions, including the medial temporal lobe (e.g., entorhinal cortex and hippocampus), anterior cingulate, posterior cingulate/precuneus, and inferior parietal lobe (Chételat et al., 2012, 2010; Frisoni, Fox, Jack, Scheltens, & Thompson, 2010; Pettigrew et al., 2017; Storandt, Mintun, Head, & Morris, 2009; Susanto, Pua, & Zhou, 2015; Tondelli et al., 2012; Wang et al., 2015). There is also some evidence from cross-sectional and longitudinal research to suggest that individuals with preclinical AD have greater whole brain atrophy (Allison et al., 2019; Fagan et al., 2009; Fotenos et al., 2008; Fox, Warrington, & Rossor, 1999; Schott, Bartlett, Fox, & Barnes, 2010). Unlike biomarkers reflecting beta-amyloid deposition and the formation of NFTs, measures of brain atrophy are sensitive, but not necessarily specific to AD.
Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum
2019, NeuroImage: ClinicalCitation Excerpt :One of the most readily available methods comes from morphometric estimates obtained using structural MRI. Structural MRI studies examining N in AD have frequently focused on hippocampal volume (Jack et al., 1992; Storandt et al., 2009; van Maurik et al., 2017), global atrophy (Fagan et al., 2009; Fox et al., 1999; Schott et al., 2010; van Maurik et al., 2017), and an “AD signature” consisting of a composite of thickness or volumetric estimates derived from regions impacted early during the course of AD (Dickerson et al., 2011; Dickerson and Wolk, 2012; Schwarz et al., 2016). A previous study, which compared multiple thickness- and volumetric-based methods for obtaining an AD signature, found that thickness-based AD signatures from FreeSurfer and Statistical Parametric Mapping (SPM) + DiReCT (the cortical thickness algorithm from Advanced Normalization Tools (ANTs)) had the strongest correlations with Braak neurofibrillary tangle stage at autopsy (Schwarz et al., 2016).
Navigating Genetic Influences on the Topography of Alzheimer's Disease
2018, Biological PsychiatryBiomarkers for Alzheimer's Disease – An Overview
2024, Macromolecular Symposia